LAT1（SLC7A5）在 Her2 阴性乳腺癌中的过表达：一个潜在的治疗靶点。
LAT1 (SLC7A5) Overexpression in Negative Her2 Group of Breast Cancer: A Potential Therapy Target.
机构信息
Department of Applied Biology, Jordan University of Science and Technology, Irbid, Jordan.
Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid, Jordan.
出版信息
Asian Pac J Cancer Prev. 2020 May 1;21(5):1453-1458. doi: 10.31557/APJCP.2020.21.5.1453.
OBJECTIVE
HER2 negative carcinomas of the breast pose a challenge for treatment due to redundancies in potential drug targets and poor patient outcomes. Our aim was to investigate the role of L-type amino acid transporter - LAT1 as a potential prognosticator and a drug target.
METHODS
In this retrospective work, we have studied the expression of LAT1 in 145 breast cancer tissues via immunohistochemistry. Overall survival analysis was used to evaluate patient outcome in various groups of our cohort.
RESULTS
Positive LAT1 expression was found in 27 (84.4%) luminal A subtype, 27 (64.3%) luminal B/triple positive subtype, 29 (82.9%) triple negative subtype, and 24 (66.7%) HER2-only positive subtype (p=0.1). Interestingly, negative correlation was found between LAT1 and HER2; where positive expression of LAT1 was found in 56 (83.6%) cases in negative HER2 group and 51 (65.4%) cases from positive HER2 group (p=0.01). Unfortunately, we were unable to report significant survival differences when LAT1 expression was studied in the negative HER2 group. Nevertheless, five incidents of mortality (out of 55) were reported in LAT1+/HER2- group compared to none in the LAT1-/HER2- group (N=11).
CONCLUSION
Our findings of overexpression of LAT1 in negative HER2 group suggest a role of this protein as prognosticator and drug target in a challenging therapeutic cohort.
.
目的
由于潜在药物靶点的冗余和患者预后不良，HER2 阴性乳腺癌的治疗具有挑战性。我们的目的是研究 L 型氨基酸转运体-LAT1 作为潜在预后标志物和药物靶点的作用。
.
方法
在这项回顾性工作中，我们通过免疫组织化学研究了 145 例乳腺癌组织中 LAT1 的表达。使用总体生存分析评估了我们队列中不同组别的患者结局。
.
结果
在 luminal A 亚型中，阳性 LAT1 表达见于 27（84.4%）例，luminal B/三阳性亚型见于 27（64.3%）例，三阴性亚型见于 29（82.9%）例，HER2 阳性仅见于 24（66.7%）例（p=0.1）。有趣的是，LAT1 与 HER2 之间存在负相关；在 HER2 阴性组中，LAT1 阳性表达见于 56（83.6%）例，而在 HER2 阳性组中，LAT1 阳性表达见于 51（65.4%）例（p=0.01）。不幸的是，当我们研究 HER2 阴性组中 LAT1 的表达时，我们无法报告显著的生存差异。尽管如此，在 LAT1+/HER2-组中报告了 5 例死亡（55 例中的 5 例），而在 LAT1-/HER2-组中没有死亡（N=11）。
.
结论
我们发现 LAT1 在 HER2 阴性组中的过度表达表明该蛋白作为预后标志物和药物靶点在具有挑战性的治疗队列中的作用。
.
Zotero 插件